As the number of people living with T1DM and T2DM grows, physicians face an increasing challenge in addressing their complicated needs. Treatment guidelines, although providing evidence-based guidance, are not prescriptive; rather, they encourage individualisation of therapy based on a patient’s clinical needs and preferences. Physicians must therefore be thoroughly informed of the benefits and disadvantages of the numerous and expanding therapeutic choices accessible to them at each stage of the disease. Because T2DM is a progressive disease, therapy with basal insulin will become unavoidable for many patients, while for others, basal insulin alone will eventually be insufficient to maintain glycaemic objectives.

The availability of IDeg in combination with insulin aspart or liraglutide offers potential for enhanced glycaemic control and a reduction in the number of daily injections required by patients. IDeg has a more consistent glucose-lowering effect from day-to-day than IGlar at steady state [Image: Shutterstock].

Please sign in to read more